Semaglutide vs tirzepatide: cost and efficacy compared
One GLP-1 agonist, one dual agonist. The efficacy gap, the pricing gap, and a cost-per-result framework to decide which fits your goals and budget.
The efficacy comparison
Both are incretin-based injectables, but they differ mechanistically: semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 agonist. The direct head-to-head, SURMOUNT-5, found tirzepatide reached 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks. Semaglutide's own STEP 1 figure was ~14.9%. On average efficacy, tirzepatide leads — but semaglutide remains highly effective and better-studied over long horizons.
The cost comparison
Compounded semaglutide is frequently priced lower than compounded tirzepatide. In our July 2026 tracking, flat-rate compounded semaglutide runs about $145/month versus roughly $186/month for flat-rate compounded tirzepatide. On the brand side, both are expensive without insurance (Wegovy/Ozempic ~$1,300–$1,400; Zepbound/Mounjaro ~$1,000–$1,350).
Cost per result
Dividing annual cost by trial-average efficacy is a rough but useful lens. Flat-rate compounded semaglutide (~$1,740/yr ÷ 14.9%) is about $117 per percentage point; flat-rate compounded tirzepatide (~$2,232/yr ÷ 20.2%) is about $110. They're remarkably close — tirzepatide buys more absolute loss, semaglutide costs less per month. An illustrative pricing comparison, not a clinical claim about individuals.
Tolerability, track record, and the practical tie-breakers
Efficacy and price get the headlines, but the decision often turns on quieter factors. Tolerability is broadly similar — both are dominated by GI side effects that cluster during titration — though individual response varies enough that some people tolerate one markedly better. Because there's no way to predict this in advance, a program allowing a penalty-free switch has real option value. Track record is another tie-breaker: semaglutide has been in widespread use longer, with a deeper real-world literature including the SELECT cardiovascular trial. Availability and pricing consistency round it out: semaglutide programs are slightly more numerous and often a bit cheaper. The honest bottom line is that neither drug is universally better — they occupy different points on the efficacy-cost-evidence frontier. What we can say cleanly is the pricing: flat-rate compounded semaglutide is the lower monthly commitment. Suitability, dose, and switching are clinical decisions for a prescriber.
Frequently asked questions
Is tirzepatide or semaglutide more effective for weight loss?
In SURMOUNT-5, tirzepatide produced greater average weight loss (20.2% vs 13.7% over 72 weeks). Semaglutide remains highly effective (~14.9% in STEP 1) with a longer track record. The best choice depends on individual priorities and clinical suitability.
Is compounded semaglutide cheaper than tirzepatide?
Generally yes. In our July 2026 tracking, flat-rate compounded semaglutide runs about $145/month versus roughly $186/month for flat-rate compounded tirzepatide. Both brand products are expensive without insurance.
Which has better cost-per-result?
They're close. Flat-rate compounded semaglutide is about $117 per percentage point of trial-average loss; tirzepatide about $110. Tirzepatide buys more absolute loss; semaglutide costs less per month. An illustrative comparison, not a clinical claim.
Can I switch between semaglutide and tirzepatide?
Switching is a clinical decision made with a prescriber based on response, tolerability, and goals. Both require their own titration schedules. Do not switch or adjust dosing without medical guidance.
Availability, switching, and the compounded-market picture
Beyond efficacy and price, the practical availability of each drug shapes real decisions, and here semaglutide has some quiet advantages worth naming. In the compounded telehealth market we track, semaglutide programs are slightly more numerous and geographically broader than tirzepatide programs, which can matter in states with thinner telehealth availability. Both drugs went through brand shortages that reshaped the compounded landscape, and both are now in a narrower regulatory environment where provider transparency matters more than the headline price. On switching: some patients start on one molecule and move to the other based on tolerability or plateau, and a program that permits this without penalty or a fresh signup fee has real value that is invisible at the initial price comparison. The compounded-market reality is that neither drug is a commodity — the pharmacy behind it, the clinical oversight wrapped around it, and the pricing structure determine value as much as the molecule choice. A cost-conscious reader is well served by treating the semaglutide-versus-tirzepatide question as the first of several decisions rather than the only one: which molecule, then which pricing model, then which provider on transparency and support. Getting the molecule right but the provider wrong can cost more, in money and outcome, than the efficacy gap between the two drugs. As always, the molecule and dose decision belongs with a prescriber who knows your history.
How to actually decide between them
If you have read this far hoping for a single verdict, the honest guidance is a short decision sequence rather than a winner. Start with your primary goal: if maximizing average weight loss is the overriding priority and cost is secondary, the trial evidence favors tirzepatide, which reached about 20.2% in the head-to-head against semaglutide 13.7%. If you value a longer real-world track record, cardiovascular-outcomes evidence, and a lower and often flatter monthly price, semaglutide is the stronger fit, and its STEP and SELECT data are deep. Next, weigh tolerability history: if you have tried one GLP-1 and struggled, the option to switch matters, so favor a provider that allows it without penalty. Then apply the budget lens honestly across the full year at your maintenance dose, not the starter price, because that is where flat-rate versus dose-tiered structures diverge by hundreds of dollars a month. Finally, bring the shortlist to a prescriber, who can weigh your medical history, other medications, and specific contraindications that no article can assess. The two drugs are close enough on cost-per-result that the provider you choose, the pricing model you land on, and your individual tolerability will usually matter more to your actual outcome than the molecule label on the vial.
Availability, switching, and the compounded-market picture
Beyond efficacy and price, the practical availability of each drug shapes real decisions, and here semaglutide has some quiet advantages worth naming. In the compounded telehealth market we track, semaglutide programs are slightly more numerous and geographically broader than tirzepatide programs, which can matter in states with thinner telehealth availability. Both drugs went through brand shortages that reshaped the compounded landscape, and both are now in a narrower regulatory environment where provider transparency matters more than the headline price. On switching: some patients start on one molecule and move to the other based on tolerability or plateau, and a program that permits this without penalty or a fresh signup fee has real value that is invisible at the initial price comparison. The compounded-market reality is that neither drug is a commodity — the pharmacy behind it, the clinical oversight wrapped around it, and the pricing structure determine value as much as the molecule choice. A cost-conscious reader is well served by treating the semaglutide-versus-tirzepatide question as the first of several decisions rather than the only one: which molecule, then which pricing model, then which provider on transparency and support. Getting the molecule right but the provider wrong can cost more, in money and outcome, than the efficacy gap between the two drugs. As always, the molecule and dose decision belongs with a prescriber who knows your history.
References
- Aronne LJ, et al. Tirzepatide vs semaglutide (SURMOUNT-5). N Engl J Med. 2025.
- Wilding JPH, et al. STEP 1. N Engl J Med. 2021.
- SemaglutideGLPOne July 2026 dataset.
- FDA labeling for Wegovy, Ozempic, Zepbound, and Mounjaro.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.